Mode
Text Size
Log in / Sign up
N/A Completed N=278

PMS Assessing the Long-term Efficacy and Safety of Nevirapine Therapy (Combined With Other ARV Drugs) in HIV-1 Positive Patients in Daily Clinical Practice.

Source: ClinicalTrials.gov NCT00736502 ↗
Enrolled (actual)
278
Serious AEs
4.3%
Results posted
Aug 2012
Primary outcomePrimary: Proportion of Patients Reporting Adverse Events — 25.5; 4.3; 9.7; 3.2 Percentage of participants

Summary

The aim of this trial is to evaluate the safety and virological and immunological efficacy of Viramune® on a background of different antiretroviral drug combinations.

Outcome Measures

OutcomeResultp-value
PRIMARY
Proportion of Patients Reporting Adverse Events
25.5; 4.3; 9.7; 3.2; 3.2; 3.6 —
SECONDARY
Virologic Response (VR)
139; 16; 123 —
SECONDARY
Change in CD4+ Cell Count From Baseline to Week 48
148.5 —

Eligibility Criteria

Inclusion criteria

The inclusion criteria follow the same criteria which are describe in the newest SPC.

Exclusion criteria

The exclusion criteria follow the same criteria which are describe in the newest SPC.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00736502). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search